Search PubMed⌕ Search

Biomedical subjects

U Magrini

Publications and source records attributed to U Magrini.

At least 91 records · Page 5Linked to original sources
PubMedDate not supplied

Nijmegen breakage syndrome-associated T-cell-rich B-cell lymphoma: case report.

In 1981 Weemaes et al. first described the Nijmegen breakage syndrome (NBS), a rare autosomal recessive disorder characterized by stunted growth, microcephaly, immunodeficiency, spontaneous chromosome instability, and a peculiar predisposition to cancer development. Most NBS-related malignancies are lymphomas, but their pathologic features have rarely been specified. We report here the case of a northern Italian 8-year-old child who, 2 years after the diagnosis of NBS, developed a diffuse large B-cell lymphoma (T cell-rich B-cell lymphoma variant). The histological and immunobiological features of the lymphoma population are analyzed and discussed in detail.

Antigens, CD20↗
PubMedDate not supplied

Tumors and dental and ocular abnormalities after treatment of infant rats with adriamycin.

In rats repeatedly treated subcutaneously as infants with adriamycin in 2 cycles of 4 treatments each, the induction of ocular and dental abnormalities and tumors was studied. Cataracts appeared from 18 to 26 days in 80% of CD rats treated with 1.15 mg/kg/day of adriamycin and from 28 to 104 days in 55% of Wistar-Lewis rats given 0.75 mg/kg/day adriamycin. Abnormal growth of incisors was observed in 30% of the CD rats and in 44% of the Wistar-Lewis rats. At lower doses, no such abnormalities were found. At about 1 year after treatment, 100% of the CD rats treated with 0.75 mg/kg/day adriamycin and about 60% of the Wistar-Lewis rats treated with 0.75 and 0.5 mg/kg/day adriamycin developed tumors, which were histologically classified.

Adenoma↗
PubMedDate not supplied

Paraneoplastic marrow alterations in patients with cancer.

BACKGROUND: Bone marrow abnormalities may be found in patients with cancers even without marrow metastases. We have seen that patients with non-hematologic neoplasias may show bone remodelling, stromal modifications, reactive changes and myelodysplastic alterations of erythro-, granulo- and megakaryocytic series comparable to those found in myelodysplastic syndromes (MDSs). METHODS AND RESULTS: At the beginning of the study 58 bone marrow biopsies (BMBs), performed in 40 patients with previously diagnosed cancer from different primary sites but without marrow metastasis (group A), were evaluated. Osseous and stromal modifications, marked reactive changes, quantitative and qualitative alterations of erythro-, granulo- and megakaryopoiesis were observed. Afterwards, 30 BMBs from 20 patients without a previous diagnosis of neoplasia (group B) were found to have features similar to those discovered in group A. Further investigations detected malignant tumors in all these cases. The findings of the two groups were compared with our former observations on myelodysplastic syndromes. The main differences between groups A-B and MDSs regarded bone remodelling, stromal modifications and reactive changes. CONCLUSION: These marrow alterations linked to a neoplasia may be considered paraneoplastic. They may cause problems for a differential diagnosis with some proliferative diseases and, above all, with primary MDSs. The reported features should prompt the pathologist to suggest a search for possible occult cancer.

Bone Marrow↗
PubMedDate not supplied

Reactive hemophagocytosis in Ki-l positive large cell lymphoma: a case study.

A case of large cell lymphoma presenting with hemophagocytic syndrome is reported. The clinicopathological findings suggested a diagnosis of malignant histiocytosis, but on the basis of immunohistological studies Ki-l lymphoma was diagnosed. Neoplastic cells expressed activation antigens such as HLA-DR, IL 2R, T10 and Ki-l, and showed high proliferative activity, but were devoid of T and B cell markers. The high percentage of reactive macrophages found in the bone marrow and lymph node probably reflected the release of lymphokines by the tumor population. The patient was treated with aggressive chemotherapy and is in complete remission at 8 months from diagnosis.

Adolescent↗